Immunic AG
Industry / private company
Location:
Planegg-Martinsried,
Germany (DE)
Validation of nuclear receptor RORγ isoform 1 as a novel host-directed antiviral target based on the modulation of cholesterol levels (2024)
Wangen C, Raithel A, Tillmanns J, Gege C, Herrmann A, Vitt D, Kohlhof H, et al.
Journal article
IMU-838, a small molecule DHODH inhibitor in phase II clinical trial for multiple sclerosis, shows potent Anti-EBV activity in cell-culture-based systems: Potential additional benefits in multiple sclerosis treatment (2021)
Marschall M, Peelen E, Müller R, Wangen C, Wagner S, Muehler A, Groeppel M, et al.
Conference contribution
Methodological development of a multi-readout assay for the assessment of antiviral drugs against sars-cov-2 (2021)
Hahn F, Häge S, Herrmann A, Wangen C, Kicuntod J, Jungnickl D, Tillmanns J, et al.
Journal article